Central City

The goal of this trial is to determine the efficacy of advanced cognitive training for cancer survivors suffering from cancer- and cancer-treatment-related cognitive dysfunction. For millions of cancer survivors, cognitive dysfunction is a prevalent, severe, and persistent problem that has long been associated with poor work-related and health-related outcomes. Evidence suggests that a significant subset of breast cancer survivors (BCS) incur cognitive changes that may persist for years after treatment. Unfortunately, the scientific basis for managing these cognitive changes is extremely limited. Available evidence from pilot studies, including our work, suggests that advanced cognitive training, which is based on the principles of neuroplasticity (ability of brain neurons to re-organize and form new neural networks), may be a viable treatment option. However, previous trials to date have been limited by lack of attention-controlled designs, small samples of BCS, or limited outcome measures. Therefore, to overcome limitations of past studies and build on our pilot results, the purpose of this 2-group, double-blind, randomized controlled trial is to conduct a full-scale efficacy trial to compare advanced cognitive training to attention control in BCS.

Researchers are evaluating a screening and multi-sub-study randomized phase II/III trial called Lung-MAP, designed for patients with previously treated non-small cell lung cancer. The trial aims to establish a genomic screening method to assign patients to biomarker-driven or non-matched sub-studies. Depending on the cancer biomarker type, participants may receive new targeted cancer therapies or combinations compared to standard care, with the goal of approving new treatments. An optional ancillary study explores patient and physician attitudes about returning genetic findings related to germline mutations. The study involves testing patient specimens to determine eligibility for various sub-studies under the Lung-MAP protocol. Patients undergo screening to analyze tumor tissue and blood samples for biomarkers including PD-L1 and c-MET. Those requiring a fresh biopsy also submit blood for circulating tumor DNA testing. Sub-study assignment depends on the molecular profile results. This screening process includes both patients progressing after prior therapy and those pre-screened before progression on current treatment. Participants provide informed consent and tumor tissue that meets quality standards for testing. Researchers collect clinical data including smoking history and performance status. Outcomes focus on screening success, such as adequate tissue submission and matching to biomarker-driven sub-studies, tracked for up to three years. The study also monitors patient and physician knowledge and preferences regarding genomic findings. Participation duration varies based on screening and sub-study assignment.

Researchers are investigating the effects of sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132) compared to standard treatments in people with previously treated extensive stage small cell lung cancer (ES-SCLC). The main goal is to compare how SG versus standard care impacts overall survival up to 4.5 years after treatment. This phase 3, global, multicenter, randomized, open-label study focuses on participants who have already received prior platinum-containing chemotherapy. Participants are randomly assigned to receive either sacituzumab govitecan or one of the standard care drugs, including topotecan, amrubicin (in Japan only), or lurbinectedin (where approved). All drugs are given by intravenous infusion. The study includes a treatment period where these medications are administered according to the protocol, with doses and schedules managed by the study teams. During the study, participants will be monitored regularly for overall survival and other health outcomes. Assessments will include imaging scans like CT or MRI to measure disease status, along with clinical evaluations and symptom monitoring. The study tracks safety and treatment effects over time, aiming for a follow-up of up to 4.5 years. Participants will have their condition reviewed throughout to evaluate how the treatments impact their survival and disease progression.

Researchers are evaluating a non-interventional study that includes multiple centers and cohorts, focusing on people diagnosed with cancer. The study aims to collect and analyze blood samples over time to profile circulating tumor DNA (ctDNA) biomarkers alongside the participants' standard cancer treatments. This approach helps to observe how ctDNA levels change during and after treatment. Participants will undergo regular blood sample collection at specific times throughout the study to monitor ctDNA biomarkers. There is no experimental treatment given as part of this study; instead, the study observes changes in ctDNA in addition to the usual care provided by their healthcare team. This design allows researchers to gather important data while participants continue their standard cancer therapies. Throughout the study, participants will provide blood samples at baseline, during treatment, and after treatment for up to five years. Researchers will analyze these samples to track changes in ctDNA over time. The study focuses on measuring these biomarker changes to enhance understanding of cancer progression and treatment response. Participants' safety and standard care are maintained, and no additional interventions are required beyond blood sample collection.